Memon Muhammad Ayoob, Khan Raisa Noor, Riaz Saman, Ain Qurat Ul, Ahmed Masood, Kumar Naresh
Department of Medicine, Government Civil Hospital, Dadu, Pakistan.
Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
J Res Med Sci. 2018 Dec 28;23:110. doi: 10.4103/jrms.JRMS_1078_17. eCollection 2018.
Diabetes mellitus is a chronic metabolic disorder of hyperglycemia. Chronic hyperglycemia produces advanced glycation end products such as the methylglyoxal (MGO) which interferes with cell functions, insulin signaling, and β-cell functions. The present study was conducted to determine the effects of berberine (BBR) therapy on serum MGO and insulin resistance in newly diagnosed type 2 diabetic patients.
The present case-control study was conducted at the Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro/Hyderabad, from March 2016 to January 2017. A sample of 200 newly diagnosed type 2 diabetic patients was divided into two groups. Group 1 received metformin 500 mg (×3 daily) and Group 2 received BBR 500 mg (×3 daily) for 3 months. Blood samples were collected at baseline and after 3 months to analyze biochemical parameters on Roche biochemical analyzer. MGO was assayed by ELISA kit and homeostasis model assessment of insulin resistance (HOMA-IR) model. SPSS version 23.0 (IBM, Incorporation, USA) analyzed the data at 95% confidence interval ( ≤ 0.05).
Baseline HOMA-IR (% IR) and MGO were found elevated in metformin and BBR groups. After 3 months of metformin and BBR therapy, the HOMA-IR (% IR) and MGO were decreased to 3.69 ± 1.13 and 2.64 ± 0.76 and 35.84 ± 12.56 and 26.64 ± 10.73 ng/dl, respectively ( = 0.0001). HOMA-IR (% IR) was improved by 40% and 73% ( = 0.0001) and MGO by 43% and 56% in metformin and BBR groups, respectively ( = 0.0001).
BBR is more effective in decreasing the serum MGO levels and insulin resistance through improved glycemic control in newly diagnosed type 2 diabetic patients.
糖尿病是一种慢性高血糖代谢紊乱疾病。慢性高血糖会产生晚期糖基化终产物，如甲基乙二醛（MGO），其会干扰细胞功能、胰岛素信号传导和β细胞功能。本研究旨在确定黄连素（BBR）治疗对新诊断2型糖尿病患者血清MGO和胰岛素抵抗的影响。
本病例对照研究于2016年3月至2017年1月在贾姆肖罗/海得拉巴的利亚卡特医学与健康科学大学医学系进行。将200例新诊断的2型糖尿病患者样本分为两组。第1组接受二甲双胍500毫克（每日3次），第2组接受BBR 500毫克（每日3次），为期3个月。在基线和3个月后采集血样，在罗氏生化分析仪上分析生化参数。通过ELISA试剂盒测定MGO，并采用胰岛素抵抗稳态模型评估（HOMA-IR）模型。SPSS 23.0版（美国IBM公司）在95%置信区间（≤0.05）分析数据。
二甲双胍组和BBR组的基线HOMA-IR（%IR）和MGO均升高。二甲双胍和BBR治疗3个月后，HOMA-IR（%IR）和MGO分别降至3.69±1.13和2.64±0.76以及35.84±12.56和26.64±10.73 ng/dl（P = 0.0001）。二甲双胍组和BBR组的HOMA-IR（%IR）分别改善了40%和73%（P = 0.0001），MGO分别改善了43%和56%（P = 0.0001）。
在新诊断的2型糖尿病患者中，BBR通过改善血糖控制，在降低血清MGO水平和胰岛素抵抗方面更有效。
